Arrowhead Pharmaceuticals
Biopharmaceutical
Traded as NASDAQ: ARWR
Russell 2000 Component
Headquarters Pasadena, CA
Key people
Christopher Anzalone, Ph.D., president and chief executive officer
Bruce Given, M.D., chief operating officer
Ken Myszkowski, MBA, CPA, chief financial officer
Website http://arrowheadpharma.com/
Arrowhead Pharmaceuticals is a publicly traded (NASDAQ: ARWR) biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[1][2] The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease.[1] The company has eight products in its pipeline, in various stages of development.
Product Indication Development phase Notes
ARO-HBV[1] Hepatitis B In Clinic Phase 1/2 Partnered with Janssen
ARO-AAT[1] Alpha-1 Antirypsin Deficiency In Clinic Phase 1/2 Orphan Drug Designation
ARO-APOC3[1] Hypertriglyceridemia Pre-Clinical Orphan Drug Designation
ARO-HIF2[1] Renal Cell Carcinoma Pre-Clinical
ARO-ENaC[1] Cystic Fibrosis Pre-Clinical
ARO-ANG3[1] Dyslipidemia Pre-Clinical Orphan Drug Designation
AMG 890[1] Cardiovascular Disease In Clinic Phase 1/2 Partnered with Amgen
ARO-AMG1[1] Undisclosed Cardiovascular Pre-Clinical Partnered with Amgen
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis.[3][4]
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[5]
On Oct. 31, 2018-- Arrowhead Pharmaceuticals Inc. closed on a $3.7 Billion License and Collaboration Agreements with Janssen to develop and commercialize ARO-HBV. As part of the overall deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[6]